Why Cardiovascular Research Needs Careful Translation
Cardiovascular and longevity research remains complex, especially in disease-informed contexts such as HLHS where careful, evidence-based professional review matters.
HeartQ is presented as a research-stage effort to explore cardiovascular and longevity-related hypotheses with QNN-assisted methods, not as therapy design, regulated care planning, or patient-specific medical advice.
The Personal Thread Behind HeartQ
Michelle L. Wu ties HeartQ to a family story involving a brother born with Hypoplastic Left Heart Syndrome, describing how that relationship shaped a research interest in clearer cardiovascular workflows and professional-review support.
The article connects that motivation with her interdisciplinary background in chemistry, biomedical engineering, applied mathematics, and quantum mechanics, alongside mentorship from UC Berkeley and MIT and graduate business study at Carnegie Mellon University.
HeartQ's Research Direction
HeartQ explores quantum/AI-assisted simulations and scaffold-related research ideas with source citations, safety limitations, and no claim of human therapeutic benefit through public materials.
HeartQ does not publish public efficacy, prediction, biological-effect, or throughput metrics unless the evidence file specifies protocol, population or data source, model version, comparator, limitations, uncertainty, and regulatory status.
As with TumorQ, any sensitive data workflow requires contracts, security controls, access rules, retention settings, and privacy review before processing.
Mission and Vision
HeartQ is presented as a long-view cardiovascular longevity research program that requires scientific, clinical, legal, and technical validation before any regulated workflow.
The article frames the work as both a tribute to people who inspire the mission and a commitment to privacy-conscious, precision-driven innovation.